Abiraterone Acetate in Molecular Apocrine Breast Cancer
Status:
Completed
Trial end date:
2018-07-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate antitumour activity of abiraterone acetate in
Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast
Cancer.